GLP-1 Weight-Loss Drugs Are a Hidden Corporate Balance Sheet Risk

The same GLP-1 drugs that are reshaping healthcare are quietly becoming a major line item on corporate profit-and-loss statements. Bank of America just disclosed it spends $250 million a year on weight-loss medications for its employees. In this episode, Lucas and Luna break down the numbers behind that figure, explore how drug costs are leaking into labor costs, and ask whether the stock market is underestimating the long-term margin impact. They look at who's exposed—from big employers to insurers—and how investors can spot the risk before it shows up in earnings. A sharp, pragmatic look at a slow-motion story that could matter more than the next Fed decision. #GLP1Drugs #CorporateHealthCosts #BankOfAmerica #WeightLossDrugs #PharmaEconomics #EmployeeBenefits #HealthcareCosts #Margins #LaborCosts #Insurance #Ozempic #Wegovy #EliLilly #NovoNordisk #Finance #BusinessPodcast #FexingoBusiness #Investing Keep every episode free: buymeacoffee.com/fexingo